Perceptive Advisors LLC Acquires 208,480 Shares of Oruka Therapeutics, Inc. $ORKA

Perceptive Advisors LLC grew its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 16.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,476,501 shares of the company’s stock after purchasing an additional 208,480 shares during the quarter. Perceptive Advisors LLC’s holdings in Oruka Therapeutics were worth $44,753,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Fairmount Funds Management LLC raised its holdings in shares of Oruka Therapeutics by 9.9% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after purchasing an additional 333,340 shares in the last quarter. Viking Global Investors LP bought a new position in shares of Oruka Therapeutics during the 3rd quarter valued at $51,280,000. Deep Track Capital LP raised its holdings in shares of Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after purchasing an additional 735,983 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Oruka Therapeutics by 38.1% during the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock valued at $74,366,000 after purchasing an additional 676,865 shares in the last quarter. Finally, Commodore Capital LP raised its holdings in shares of Oruka Therapeutics by 23.5% during the 3rd quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock valued at $33,711,000 after purchasing an additional 333,340 shares in the last quarter. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Trading Up 4.7%

NASDAQ:ORKA opened at $70.88 on Thursday. Oruka Therapeutics, Inc. has a 1 year low of $10.77 and a 1 year high of $91.00. The firm’s fifty day simple moving average is $64.29 and its 200 day simple moving average is $44.86. The firm has a market capitalization of $4.27 billion, a PE ratio of -36.54 and a beta of -0.26.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. As a group, analysts anticipate that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ORKA. Stifel Nicolaus raised their price target on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, April 21st. Wedbush set a $165.00 price target on shares of Oruka Therapeutics in a report on Monday, April 27th. Piper Sandler restated an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Finally, Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Oruka Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $131.30.

Insider Activity

In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.69, for a total value of $120,494.01. Following the sale, the chief executive officer directly owned 925,580 shares in the company, valued at $64,503,670.20. This trade represents a 0.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Carl Dambkowski sold 105,000 shares of the firm’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $58.97, for a total transaction of $6,191,850.00. Following the completion of the sale, the director owned 73,743 shares in the company, valued at $4,348,624.71. This represents a 58.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 183,820 shares of company stock valued at $11,507,840. 23.49% of the stock is owned by corporate insiders.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.